Identification of New Drug Targets and Resistance Mechanisms in Mycobacterium tuberculosis

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Ioerger, Thomas R ^a   O'Malley, Theresa ^b   Liao, Reiling ^c   Guinn, Kristine M ^d   Hickey, Mark J ^c   Mohaideen, Nilofar ^a   Murphy, Kenan C ^e   Boshoff, Helena I M ^f   Mizrahi, Valerie ^g   Rubin, Eric J ^d   Sassetti, Christopher M ^e,h   Barry III, Clifton E ^f   Sherman, David R ^c   Parish, Tanya ^b   Sacchettini, James C ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

^b INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

^c SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^g UNIVERSITY OF CAPE TOWN   (South Africa)

^h HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE TRANSFER RNA LIGASE; GENOMIC DNA; MYCOLIC ACID; POLYKETIDE SYNTHASE; TUBERCULOSTATIC AGENT;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; ASPS GENE; BACTERIAL CELL WALL; BACTERIAL GENE; BACTERIAL SECRETION SYSTEM; BACTERIUM MUTANT; CONTROLLED STUDY; CRYSTALLIZATION; DRUG RESEARCH; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; ECCB3 GENE; GENETIC ENGINEERING; GENETIC POLYMORPHISM; GENOME ANALYSIS; MEMBRANE TRANSPORT; MINIMUM INHIBITORY CONCENTRATION; MMPL3 GENE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PKS13 GENE; PROTEIN SYNTHESIS; RNA TRANSLATION; SEQUENCE ANALYSIS; TYPE VII SECRETION SYSTEM; VALIDATION PROCESS; WHOLE CELL;

ANTITUBERCULAR AGENTS; ASPARTIC ACID ENDOPEPTIDASES; BACTERIAL PROTEINS; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, BACTERIAL; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MYCOBACTERIUM TUBERCULOSIS; POLYKETIDE SYNTHASES; SEQUENCE ANALYSIS, DNA;

EID: 84884505005     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0075245     Document Type: Article

References (71)

1. World Health Organization (2010) Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. Report No WHO/HTM/TB/20103.
2. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL, (2007) Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 6: 29-40. doi:10.1038/nrd2201. PubMed: 17159923.
3. Murphy KC, Marinus MG, (2010) RecA-independent single-stranded DNA oligonucleotide-mediated mutagenesis. F1000. Biol Reprod 2: 56.
4. Andries K, Verhasselt P, Guillemont J, Göhlmann HW, Neefs JM, et al. (2005) A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307: 223-227. doi:10.1126/science.1106753. PubMed: 15591164.
5. Koul A, Dendouga N, Vergauwen K, Molenberghs B, Vranckx L, et al. (2007) Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat Chem Biol 3: 323-324. doi:10.1038/nchembio884. PubMed: 17496888.
6. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ, (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46: 3-26. doi:10.1016/S0169-409X(00)00129-0. PubMed: 11259830.
7. Ioerger TR, Feng Y, Ganesula K, Chen X, Dobos KM, et al. (2010) Variation among genome sequences of H37Rv strains of Mycobacterium tuberculosis from multiple laboratories. J Bacteriol 192: 3645-3653. doi:10.1128/JB.00166-10. PubMed: 20472797.
8. Banu S, Honoré N, Saint-Joanis B, Philpott D, Prévost MC, et al. (2002) Are the PE-PGRS proteins of Mycobacterium tuberculosis variable surface antigens? Mol Microbiol 44: 9-19. doi:10.1046/j.1365-2958.2002.02813.x. PubMed: 11967065.
9. Griffin JE, Gawronski JD, Dejesus MA, Ioerger TR, Akerley BJ, et al. (2011) High-resolution phenotypic profiling defines genes essential for mycobacterial growth and cholesterol catabolism. PLOS Pathog 7: e1002251. PubMed: 21980284.
10. van Kessel JC, Hatfull GF, (2007) Recombineering in Mycobacterium tuberculosis. Nat Methods 4: 147-152. doi:10.1038/nmeth996. PubMed: 17179933.
11. Bitter W, Houben EN, Bottai D, Brodin P, Brown EJ, et al. (2009) Systematic genetic nomenclature for type VII secretion systems. PLOS Pathog 5: e1000507. PubMed: 19876390.
12. Maciag A, Dainese E, Rodriguez GM, Milano A, Provvedi R, et al. (2007) Global analysis of the Mycobacterium tuberculosis Zur (FurB) regulon. J Bacteriol 189: 730-740. doi:10.1128/JB.01190-06. PubMed: 17098899.
13. Serafini A, Boldrin F, Palù G, Manganelli R, (2009) Characterization of a Mycobacterium tuberculosis ESX-3 conditional mutant: essentiality and rescue by iron and zinc. J Bacteriol 191: 6340-6344. doi:10.1128/JB.00756-09. PubMed: 19684129.
14. Siegrist MS, Unnikrishnan M, McConnell MJ, Borowsky M, Cheng TY, et al. (2009) Mycobacterial Esx-3 is required for mycobactin-mediated iron acquisition. Proc Natl Acad Sci U S A 106: 18792-18797. doi:10.1073/pnas.0900589106. PubMed: 19846780.
15. Domenech P, Reed MB, Barry CE 3rd, (2005) Contribution of the Mycobacterium tuberculosis MmpL protein family to virulence and drug resistance. Infect Immun 73: 3492-3501. doi:10.1128/IAI.73.6.3492-3501.2005. PubMed: 15908378.
16. La Rosa V, Poce G, Canseco JO, Buroni S, Pasca MR, et al. (2012) MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212. Antimicrob Agents Chemother 56: 324-331. doi:10.1128/AAC.05270-11. PubMed: 22024828.
17. Tahlan K, Wilson R, Kastrinsky DB, Arora K, Nair V, et al. (2012) SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob Agents Chemother 56: 1797-1809. doi:10.1128/AAC.05708-11. PubMed: 22252828.
18. Grzegorzewicz AE, Pham H, Gundi VA, Scherman MS, North EJ, et al. (2012) Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane. Nat Chem Biol 8: 334-341. doi:10.1038/nchembio.794. PubMed: 22344175.
19. Tullius MV, Harmston CA, Owens CP, Chim N, Morse RP, et al. (2011) Discovery and characterization of a unique mycobacterial heme acquisition system. Proc Natl Acad Sci U S A 108: 5051-5056. doi:10.1073/pnas.1009516108. PubMed: 21383189.
20. Portevin D, de Sousa-D'Auria C, Montrozier H, Houssin C, Stella A, et al. (2005) The acyl-AMP ligase FadD32 and AccD4-containing acyl-CoA carboxylase are required for the synthesis of mycolic acids and essential for mycobacterial growth: identification of the carboxylation product and determination of the acyl-CoA carboxylase components. J Biol Chem 280: 8862-8874. PubMed: 15632194.
21. Carroll P, Faray-Kele MC, Parish T, (2011) Identifying vulnerable pathways in Mycobacterium tuberculosis by using a knockdown approach. Appl Environ Microbiol 77: 5040-5043. doi:10.1128/AEM.02880-10. PubMed: 21642404.
22. Gavalda S, Léger M, van der Rest B, Stella A, Bardou F, et al. (2009) The Pks13/FadD32 crosstalk for the biosynthesis of mycolic acids in Mycobacterium tuberculosis. J Biol Chem 284: 19255-19264. doi:10.1074/jbc.M109.006940. PubMed: 19436070.
23. Frueh DP, Arthanari H, Koglin A, Vosburg DA, Bennett AE, et al. (2008) Dynamic thiolation-thioesterase structure of a non-ribosomal peptide synthetase. Nature 454: 903-906. doi:10.1038/nature07162. PubMed: 18704088.
24. Verma A, Saraf SK, (2008) 4-thiazolidinone--a biologically active scaffold. Eur J Med Chem 43: 897-905. doi:10.1016/j.ejmech.2007.07.017. PubMed: 17870209.
25. Briand C, Poterszman A, Eiler S, Webster G, Thierry J, et al. (2000) An intermediate step in the recognition of tRNA(Asp) by aspartyl-tRNA synthetase. J Mol Biol 299: 1051-1060. doi:10.1006/jmbi.2000.3819. PubMed: 10843857.
26. Eriani G, Cavarelli J, Martin F, Dirheimer G, Moras D, et al. (1993) Role of dimerization in yeast aspartyl-tRNA synthetase and importance of the class II invariant proline. Proc Natl Acad Sci U S A 90: 10816-10820. doi:10.1073/pnas.90.22.10816. PubMed: 8248175.
27. Milano A, Pasca MR, Provvedi R, Lucarelli AP, Manina G, et al. (2009) Azole resistance in Mycobacterium tuberculosis is mediated by the MmpS5-MmpL5 efflux system. Tuberculosis (Edinb) 89: 84-90. doi:10.1016/j.tube.2008.08.003. PubMed: 18851927.
28. Hasan A, Thomas NF, Gapil S, (2011) Synthesis, characterization and antifungal evaluation of 5-substituted-4-amino-1,2,4-triazole-3-thioesters. Molecules 16: 1297-1309. doi:10.3390/molecules16021297. PubMed: 21278680.
29. DeBarber AE, Mdluli K, Bosman M, Bekker LG, Barry CE 3rd, (2000) Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 97: 9677-9682. doi:10.1073/pnas.97.17.9677. PubMed: 10944230.
30. Baulard AR, Betts JC, Engohang-Ndong J, Quan S, McAdam RA, et al. (2000) Activation of the pro-drug ethionamide is regulated in mycobacteria. J Biol Chem 275: 28326-28331. PubMed: 10869356.
31. Vannelli TA, Dykman A, Ortiz de Montellano PR, (2002) The antituberculosis drug ethionamide is activated by a flavoprotein monooxygenase. J Biol Chem 277: 12824-12829. doi:10.1074/jbc.M110751200. PubMed: 11823459.
32. Hanoulle X, Wieruszeski JM, Rousselot-Pailley P, Landrieu I, Locht C, et al. (2006) Selective intracellular accumulation of the major metabolite issued from the activation of the prodrug ethionamide in mycobacteria. J Antimicrob Chemother 58: 768-772. doi:10.1093/jac/dkl332. PubMed: 16895935.
33. Sassetti CM, Rubin EJ, (2003) Genetic requirements for mycobacterial survival during infection. Proc Natl Acad Sci U S A 100: 12989-12994. doi:10.1073/pnas.2134250100. PubMed: 14569030.
34. Yano T, Li LS, Weinstein E, Teh JS, Rubin H, (2006) Steady-state kinetics and inhibitory action of antitubercular phenothiazines on mycobacterium tuberculosis type-II NADH-menaquinone oxidoreductase (NDH-2). J Biol Chem 281: 11456-11463. doi:10.1074/jbc.M508844200. PubMed: 16469750.
35. Vilchèze C, Weisbrod TR, Chen B, Kremer L, Hazbón MH, et al. (2005) Altered NADH/NAD+ ratio mediates coresistance to isoniazid and ethionamide in mycobacteria. Antimicrob Agents Chemother 49: 708-720. doi:10.1128/AAC.49.2.708-720.2005. PubMed: 15673755.
36. Timmers LF, Caceres RA, Vivan AL, Gava LM, Dias R, et al. (2008) Structural studies of human purine nucleoside phosphorylase: towards a new specific empirical scoring function. Arch Biochem Biophys 479: 28-38. doi:10.1016/j.abb.2008.08.015. PubMed: 18790691.
37. Rozwarski DA, Grant GA, Barton DH, Jacobs WR Jr., Sacchettini JC, (1998) Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. Science 279: 98-102. doi:10.1126/science.279.5347.98. PubMed: 9417034.
38. Freundlich JS, Wang F, Vilchèze C, Gulten G, Langley R, et al. (2009) Triclosan derivatives: towards potent inhibitors of drug-sensitive and drug-resistant Mycobacterium tuberculosis. Chemmedchem 4: 241-248. doi:10.1002/cmdc.200800261. PubMed: 19130456.
39. Wilson R, Kumar P, Parashar V, Vilchèze C, Veyron-Churlet R, et al. (2013) Antituberculosis thiophenes define a requirement for Pks13 in mycolic acid biosynthesis. Nat Chem Biol 9: 499-506. doi:10.1038/nchembio.1277. PubMed: 23770708.
40. Yanagisawa T, Lee JT, Wu HC, Kawakami M, (1994) Relationship of protein structure of isoleucyl-tRNA synthetase with pseudomonic acid resistance of Escherichia coli. A proposed mode of action of pseudomonic acid as an inhibitor of isoleucyl-tRNA synthetase. J Biol Chem 269: 24304-24309. PubMed: 7929087.
41. Jarvest RL, Berge JM, Berry V, Boyd HF, Brown MJ, et al. (2002) Nanomolar inhibitors of Staphylococcus aureus methionyl tRNA synthetase with potent antibacterial activity against gram-positive pathogens. J Med Chem 45: 1959-1962. doi:10.1021/jm025502x. PubMed: 11985462.
42. Ghanekar K, McBride A, Dellagostin O, Thorne S, Mooney R, et al. (1999) Stimulation of transposition of the Mycobacterium tuberculosis insertion sequence IS6110 by exposure to a microaerobic environment. Mol Microbiol 33: 982-993. doi:10.1046/j.1365-2958.1999.01539.x. PubMed: 10476032.
43. McEvoy CR, Falmer AA, Gey van Pittius NC, Victor TC, van Helden PD, et al. (2007) The role of IS6110 in the evolution of Mycobacterium tuberculosis. Tuberculosis (Edinb) 87: 393-404. doi:10.1016/j.tube.2007.05.010. PubMed: 17627889.
44. Poole K, (2007) Efflux pumps as antimicrobial resistance mechanisms. Ann Med 39: 162-176. doi:10.1080/07853890701195262. PubMed: 17457715.
45. Braibant M, Gilot P, Content J, (2000) The ATP binding cassette (ABC) transport systems of Mycobacterium tuberculosis. FEMS Microbiol Rev 24: 449-467. doi:10.1111/j.1574-6976.2000.tb00550.x. PubMed: 10978546.
46. De Rossi E, Arrigo P, Bellinzoni M, Silva PA, Martín C, et al. (2002) The multidrug transporters belonging to major facilitator superfamily in Mycobacterium tuberculosis. Mol Med 8: 714-724. PubMed: 12520088.
47. Amaral L, Martins M, Viveiros M, (2007) Enhanced killing of intracellular multidrug-resistant Mycobacterium tuberculosis by compounds that affect the activity of efflux pumps. J Antimicrob Chemother 59: 1237-1246. doi:10.1093/jac/dkl500. PubMed: 17218448.
48. Louw GE, Warren RM, Gey van Pittius NC, McEvoy CR, Van Helden PD, et al. (2009) A balancing act: efflux/influx in mycobacterial drug resistance. Antimicrob Agents Chemother 53: 3181-3189. doi:10.1128/AAC.01577-08. PubMed: 19451293.
49. Colangeli R, Helb D, Sridharan S, Sun J, Varma-Basil M, et al. (2005) The Mycobacterium tuberculosis iniA gene is essential for activity of an efflux pump that confers drug tolerance to both isoniazid and ethambutol. Mol Microbiol 55: 1829-1840. doi:10.1111/j.1365-2958.2005.04510.x. PubMed: 15752203.
50. Ramón-García S, Martín C, Aínsa JA, De Rossi E, (2006) Characterization of tetracycline resistance mediated by the efflux pump Tap from Mycobacterium fortuitum. J Antimicrob Chemother 57: 252-259. doi:10.1093/jac/dki436. PubMed: 16373429.
51. Ramón-García S, Martín C, Thompson CJ, Aínsa JA, (2009) Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth. Antimicrob Agents Chemother 53: 3675-3682. doi:10.1128/AAC.00550-09. PubMed: 19564371.
52. Ramón-García S, Martín C, De Rossi E, Aínsa JA, (2007) Contribution of the Rv2333c efflux pump (the Stp protein) from Mycobacterium tuberculosis to intrinsic antibiotic resistance in Mycobacterium bovis BCG. J Antimicrob Chemother 59: 544-547. doi:10.1093/jac/dkl510. PubMed: 17242035.
53. Pasca MR, Guglierame P, Arcesi F, Bellinzoni M, De Rossi E, et al. (2004) Rv2686c-Rv2687c-Rv2688c, an ABC fluoroquinolone efflux pump in Mycobacterium tuberculosis. Antimicrob Agents Chemother 48: 3175-3178. doi:10.1128/AAC.48.8.3175-3178.2004. PubMed: 15273144.
54. Louw GE, Warren RM, Gey van Pittius NC, Leon R, Jimenez A, et al. (2011) Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux. Am J Respir Crit Care Med 184: 269-276. doi:10.1164/rccm.201011-1924OC. PubMed: 21512166.
55. Teo JW, Thayalan P, Beer D, Yap AS, Nanjundappa M, et al. (2006) Peptide deformylase inhibitors as potent antimycobacterial agents. Antimicrob Agents Chemother 50: 3665-3673. doi:10.1128/AAC.00555-06. PubMed: 16966397.
56. Boshoff HI, Barry CE 3rd, (2005) Tuberculosis- metabolism and respiration in the absence of growth. Nat Rev Microbiol 3: 70-80. doi:10.1038/nrmicro1065. PubMed: 15608701.
57. Gomez JE, McKinney JD, (2004) M. tuberculosis persistence, latency, and drug tolerance. Tuberculosis (Edinb) 84: 29-44. doi:10.1016/j.tube.2003.08.003.
58. McKinney JD, Höner zu Bentrup K, Muñoz-Elías EJ, Miczak A, Chen B, et al. (2000) Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature 406: 735-738. doi:10.1038/35021074. PubMed: 10963599.
59. Sherman DR, Voskuil M, Schnappinger D, Liao R, Harrell MI, et al. (2001) Regulation of the Mycobacterium tuberculosis hypoxic response gene encoding alpha-crystallin. Proc Natl Acad Sci U S A 98: 7534-7539. doi:10.1073/pnas.121172498. PubMed: 11416222.
60. Rustad TR, Harrell MI, Liao R, Sherman DR, (2008) The enduring hypoxic response of Mycobacterium tuberculosis. PLOS ONE 3: e1502. doi:10.1371/journal.pone.0001502. PubMed: 18231589.
61. Manos-Turvey A, Bulloch EM, Rutledge PJ, Baker EN, Lott JS, et al. (2010) Inhibition studies of Mycobacterium tuberculosis salicylate synthase (MbtI). Chemmedchem 5: 1067-1079. doi:10.1002/cmdc.201000137. PubMed: 20512795.
62. Vasan M, Neres J, Williams J, Wilson DJ, Teitelbaum AM, et al. (2010) Inhibitors of the salicylate synthase (MbtI) from Mycobacterium tuberculosis discovered by high-throughput screening. Chemmedchem 5: 2079-2087. doi:10.1002/cmdc.201000275. PubMed: 21053346.
63. Maddry JA, Ananthan S, Goldman RC, Hobrath JV, Kwong CD, et al. (2009) Antituberculosis activity of the molecular libraries screening center network library. Tuberculosis (Edinb) 89: 354-363. doi:10.1016/j.tube.2009.07.006. PubMed: 19783214.
64. Ananthan S, Faaleolea ER, Goldman RC, Hobrath JV, Kwong CD, et al. (2009) High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv. Tuberculosis (Edinb) 89: 334-353. doi:10.1016/j.tube.2009.05.008. PubMed: 19758845.
65. Ballell L, Bates RH, Young RJ, Alvarez-Gomez D, Alvarez-Ruiz E, et al. (2013) Fueling open-source drug discovery: 177 small-molecule leads against tuberculosis. Chemmedchem 8: 313-321. doi:10.1002/cmdc.201200428. PubMed: 23307663.
66. Collins L, Franzblau SG, (1997) Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob Agents Chemother 41: 1004-1009. PubMed: 9145860.
67. Sirgel FA, Wiid IJ, van Helden PD, (2009) Measuring minimum inhibitory concentrations in mycobacteria. Methods Mol Biol 465: 173-186. doi:10.1007/978-1-59745-207-6_11. PubMed: 20560078.
68. Belisle JT, Mahaffey SB, Hill PJ, (2009) Isolation of mycobacterium species genomic DNA. Methods Mol Biol 465: 1-12. doi:10.1007/978-1-59745-207-6_1. PubMed: 20560080.
69. Wei JR, Krishnamoorthy V, Murphy K, Kim JH, Schnappinger D, et al. (2011) Depletion of antibiotic targets has widely varying effects on growth. Proc Natl Acad Sci U S A 108: 4176-4181. doi:10.1073/pnas.1018301108. PubMed: 21368134.
70. Sambandamurthy VK, Derrick SC, Hsu T, Chen B, Larsen MH, et al. (2006) Mycobacterium tuberculosis DeltaRD1 DeltapanCD: a safe and limited replicating mutant strain that protects immunocompetent and immunocompromised mice against experimental tuberculosis. Vaccine 24: 6309-6320. doi:10.1016/j.vaccine.2006.05.097. PubMed: 16860907.
71. Lamichhane G, Zignol M, Blades NJ, Geiman DE, Dougherty A, et al. (2003) A postgenomic method for predicting essential genes at subsaturation levels of mutagenesis: application to Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 100: 7213-7218. doi:10.1073/pnas.1231432100. PubMed: 12775759.